SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) today announced that Dr. Qun Dang gave an oral presentation during the 235th American Chemical Society (ACS) National Meeting & Exposition in New Orleans, LA, discussing MB07803, the Company’s second-generation fructose-1,6-bisphosphatase (FBPase) inhibitor for the treatment of type 2 diabetes. The presentation, entitled “Discovery of a Second-Generation FBPase Inhibitor, MB07803, with Reduced Metabolism and Improved Oral Bioavailability,” was Metabasis’ first public scientific disclosure on this candidate. The Company also announced today that Metabasis’ presentation on MB07803 will be highlighted in an upcoming issue of Chemical & Engineering News covering the ACS meeting.
